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Abstract
Intro
A mechanical limitation of modern linacs affecting the quality of radiotherapy treatments of
large tumor volumes is the travel length of multicollimator leaves. Considering this limitation,
research was carried out to evaluate the dosimetric differences between a split-field fixed-jaw
volumetric arc radiotherapy (SF-FJ VMAT) technique and a jaw tracking VMAT (JT VMAT)
technique for the treatment of prostate cancer with involved lymph nodes.
Methods
Plans for 16 patients treated with the same dose regimen were created using both techniques.
Initial JT-VMAT plans were planned with two arcs to encompass the entire tumor volume
without jaw restrictions and jaw tracking feature activated. SF-FJ VMAT initial plans utilized
three arcs with each arc focused on different areas of the tumor volume and X-jaws restricted to
≤15cm. Identical boost plans were used for each patient. Dosimetric and statistical comparison of
plans were conducted using dose value histogram data and paired t-tests.
Results
Monitor units were found to be on average much higher (1028.04 ± 149.45 MUs) in the SF-FJ
VMAT plans while average PTV45 V105 (1.34 ± 1.52 cGy) and average PTV45 D2% (8278.23 ±
54.54 cGy) were found to be significantly higher in the JT VMAT plans after statistical analysis.
Sparing of small bowel and rectum was very similar. Combined femurs had statistically
significant higher average max dose (4659.27 ± 374.02 cGy) when using JT VMAT technique.
Bladder sparing was mixed with average V80 (5.22 ± 4.21 cGy) and mean dose (4507.34 ±
826.21 cGy) being greater in the SF-FJ VMAT plans while V 50 (33.01 ± 18.55 cGy) was greater
in the JT VMAT plans.
Conclusion
Dosimetric advantages were found to be mostly in favor of the SF-FJ VMAT plans, however the
resulting higher monitor units can lead to significantly longer treatment times. A cost-benefit
analysis regarding potential advantages of this technique will have to be undertaken on a caseby-case basis with the decision ultimately being physician-dependent.

Introduction
Approximately 190,000 men are diagnosed with prostate cancer in the United States
every year. It is the most diagnosed cancer in males with about 1 in 9 being diagnosed in their
lifetime and an increase in incidence with each passing decade 1. More than 65% of prostate
cancers arise in men 65 years or older resulting in an average diagnosis age of 67 years. An
estimated 33,000 deaths will occur in 2020 with a projected decrease in mortality due to better
screening, earlier detection, and advances in treatment. The most common histology found in
prostate tumors is adenocarcinoma with stage of disease determined according to the
classification set by the American Joint Committee on Cancer2. A histologic grading system was
developed by Gleason based on degree of differentiation and morphology of tumor. Gleason
scores are a main prognosis indicator with higher scores denoting a more aggressive and invasive
tumor2.
Prostate cancer can spread by direct extension to the periprostatic tissue, seminal vesicles,
bladder, and rectum. It can also invade perineural spaces, spread through lymphatics, and via
blood vessels to create distant metastasis with bone being the most common site. Lymphatic
spread usually starts to the periprostatic and obturator nodes followed by spread to the internal
iliac, external iliac, common iliac, and periaortic nodes3. Treatment is varied and usually depends
on a number of factors such as patient health status, age, life expectancy, histologic grade, and
potential side effects3. Patients with early stage detection of a tumor have an excellent outlook,
especially since prostate cancer is known to have a generally slow development. For patients
with a life expectancy of less than 10 years, low Gleason score, and a T1-T2 staged tumor,
observation is a valid treatment option. Additionally, if the disease is still localized to the
prostate, such as in T1 or T2 tumors, a radical prostatectomy is a viable option for patients with a

life expectancy of at least 10 years2. In cases of stage T3 disease, where cancer has extended
beyond the prostate, radiation therapy with hormonal treatment is seen as the appropriate course
of treatment.
Historically, pelvic lymph nodes were proactively included in radiation therapy treatment
fields as a way to reduce the risk of metastasis. This was done through a treatment technique
known as a four-field box. With this technique, the upper border of the anteroposterior field was
set at the mid-sacral level, the lower border was set at the inferior aspect of the prostate gland,
and the lateral borders determined by a margin of 1.5-2cm from the pelvic brim. Posterior border
for the lateral fields was the posterior ischium with the anterior border being 1cm posterior to the
pubic symphysis. Field size was usually 15x15cm at patient surface and a reduced field size was
determined for treatment of prostate and seminal vesicles followed by final cone down to include
only the prostate2.
As the advancement of technology and treatment delivery techniques have progressed,
intensity modulated radiation therapy (IMRT) and image guided radiation therapy (IGRT) have
become the standard for treating prostate cancer. The use of such treatment techniques allows for
the delivery of higher doses to the target volume while reducing excessive dose to local organsa-risk (OARs) such as the bladder, rectum, and femoral heads 3. To undergo IMRT, patients are
simulated with a CT simulator in the supine position using a leg immobilization device. Patients
are usually requested to have an empty rectum and a full bladder at the time of simulation. The
scan is typically completed from the diaphragm to mid-femur with the isocenter set within the
prostate. Afterwards, the scanned data is transferred to an advanced treatment planning system
where the CT scan data is reconstructed in 3D allowing for the contouring of critical structures

and target volumes as well as the ability to plan using IMRT by physicians, medical physicists,
and medical dosimetrists2.
IMRT has been used widely in the treatment of various cancers. When using static field
IMRT, five or more beam angles are used in conjunction with a multileaf collimator (MLC)
which modulates the dose in the treatment field to achieve high conformality to target volumes
with less dose to adjacent organs at risk2. For prostate cancer patients that have advanced disease
with involved lymph nodes, such as the case of T3 staged prostate cancers, a larger field is
needed to provide adequate coverage to the planning target volume (PTV). Various methods
have been utilized to both meet coverage goals and dose constraints for advanced cancers that
have larger PTVs.
A mechanical limitation that can come into play with large treatment portals is the travel
length of the MLCs. Varian linear accelerators commonly used in radiation therapy treatments
have a maximum travel span of 15cm for their MLCs in the X-direction. With field sizes smaller
than 15cm, the MLCs can provide adequate coverage and dose modulation from both sides,
while with larger fields the entire field may not be reached by the MLCs resulting in suboptimal
modulation to target structures4. A split-field technique has been used in an attempt to provide
adequate coverage to fields larger than 15cm, although it has been noted that such method can
result in match-line dose inhomogeneities, excessive MLC segments, and higher treatment
times5. A fixed jaw technique method was proposed by Srivastava et al where the X jaw was
fixed to a width of 13cm to 14.5cm for all fields during optimization and compared to a splitfield planning technique that allowed the creation of subfields based on MLC constraints in five
head and neck cancer patients with extensive lymph node involvement. It was found that dose
coverage for both the target volume and OARs to be comparable while the fixed jaw technique

had overall shorter treatment times, better dose uniformity, and lower monitor units (MUs).
Higher number of segments and MUs have been correlated with long term complications and
higher whole body irradiation dose which resulted in the fixed jaw technique being superior in
this case5.
An extension of IMRT is volumetric modulated arc therapy (VMAT) where radiation
therapy treatments are delivered using a continually rotating gantry and continuously moving
MLCs to deliver a modulated dose of radiation over the treatment area. Employed in the
treatment of many of the same cancers, VMAT has been found to deliver similar, and at times,
superior dosimetric results with less time and more accuracy 4. An example of this is in an
evaluation conducted to compare fixed-jaw static field IMRT treatment plans with VMAT
treatment plans in the treatment of synchronous bilateral breast cancer. The study found the MUs
of the VMAT plans were up to 1.45 times lower than the IMRT plans with comparable decreases
in treatment times. All plans, however, showed similar conformity indexes and the fixed-jaw
static field IMRT plan showed somewhat better target coverage 6.
With the same MLC span limitation present in both VMAT as well as IMRT techniques,
an effort was made by Huang et al.7 to determine whether VMAT or static field IMRT was most
beneficial in treating advanced cervical cancers with involved lymph nodes. The VMAT plans
consisted of two arcs with a 15cm field width restriction applied using the collimator jaws in the
X direction. The IMRT plans were composed of seven evenly spaced static fields that used
sliding window leaf motion for dose modulation. Once again it was found that total treatment
MUs to be 42.7% less for the jaw-width restricted VMAT treatments with a 41.2% decrease in
treatment time, which translated to 3 minutes shorter compared to the 7-field IMRT plans.

Furthermore, it was noted that median dose to OARs including rectum, bladder, small intestine,
and femoral heads were also lower for the jaw width restricted VMAT plans.
Rossi et al.8 carried out a similar comparison between an IMRT plan and a number of
VMAT plans to find the best planning approach focused on large planning target volumes that
included lymph node involvement in the pelvis. A total of 15 patients with both vulvar cancer
and anorectal carcinoma were planned for using three VMAT plans and a 7-field static IMRT
plan. The first VMAT plan consisted of two arcs with no limitations imposed on the field size,
the second VMAT plan utilized two arcs with an asymmetrical field size restriction on each arc,
and the final VMAT plan consisted of one arc with the field size restricted to the central PTV
while the 2nd arc was divided in two half-arcs with the field size restricted to focus laterally on
the lymph node vessels. The results showed that the VMAT plan with one full arc and two halfarcs had a lower maximum dose and better PTV coverage. Dose to the OARs was found to be
equal or better for the same techniques when compared with the other methods, and the
differences seemed to be the greatest when compared to the VMAT plan with no field size
limitation.
Transmission through the multileaf collimator can also be a concern when treating
patients using IMRT. Treating large target volumes can result in an increase in MLC
transmission as the field size and beam energy increases 9. A feature available in Varian linear
accelerators that can help minimize transmission through MLC leaves is the jaw tracking feature.
This option allows for tracking of the MLC aperture during treatment delivery by the jaws which
can have dosimetric benefits since it has been determined that transmission through MLCs and
jaw together can be less than 0.1%9. With less leakage, adjacent critical structures are further
shielded as the dose fall off is minimized to surrounding OARs. To determine what type of

patients and OARs would benefit the most as a well as ascertain the benefits of using the jaw
tracking technique, Feng et al.9 compared IMRT plans for various types of cancer patients using
jaw tracking and static jaw techniques. Plans were completed for 28 patients that included
esophageal, abdomen, prostate, head and neck, rectal, and cervical cancers. Dose value
histograms (DVH) and isodose curves were then evaluated for each of the plans. Results showed
that the jaw tracking technique IMRT plans had significantly lower percentages of V 5, V10, V20,
V30, V40, and lower mean doses to the whole body. Of note was the substantial reduction by the
jaw tracking technique of maximum dose to brainstem, spinal cord, lens, and eyes with overall
dose reduction ranging from 2.2% to 28.6% compared to the static jaw method 9.
The effect of jaw tracking was further analyzed by Wu et al. 10 in an evaluation of the
dosimetric impact of this technique on similar VMAT treatment plans for different cancer
patients. A total of 80 VMAT plans were composed for 40 thoracic, head and neck, pelvic, and
abdominal cancer patients using similar plan parameters. A comparison was carried out using
one plan having the jaw tracking feature on and a second plan having the four jaws at a fixed
position equal to the most retracted position of the jaw tracking plan. OAR doses were assessed
using the DVH to determine the differences between both techniques. A reduction in mean dose
of between 0.09% and 7.81% to various OARs was noticed with a maximum dose decrease of
between 0.06% to 6.76% when using the jaw tracking method. Similarly, Thongsawad et al. 11
found in a comparison of VMAT plans with and without jaw tracking that the reduction of
integral dose in jaw tracking VMAT plans was statistically significant. It was also determined
that the same technique was effective in reducing V 5 and V10 to organs at risk such as bladder,
rectum, and lung.

The jaw tracking feature and fixed-jaw treatment techniques have been utilized in the
past to study the dosimetric impact of such methods on a wide variety of cancers. Among these,
the treatment of large target volumes, such as in the case of advanced prostate cancer with
involved pelvic nodes, can prove to be challenging especially when attempting to attain adequate
coverage, achieve appropriate dose modulation, and meet dose-volume constraints to OARs. The
purpose of this study is to conduct a dosimetric evaluation of fixed-jaw and jaw-tracking VMAT
plans for the treatment of prostate cancers with lymph node involvement. All patients will be
planned with two VMAT techniques, one using a split-field fixed-jaw (SF-FJ VMAT) technique
with set field sizes of less than or equal to 15cm and a second jaw tracking (JT VMAT)
technique employing the use of the jaw tracking feature. The researcher hypothesizes that the
SF-FJ VMAT plans will yield better target coverage, better dose conformity to tumor volumes,
and increased sparing of OARs.
Materials and Methods
Patient Selection
Prior to commencing this retrospective study, a research protocol following hospitalestablished guidelines was submitted for approval to the hospital institutional review board (IRB)
in addition to the Grand Valley State University IRB. Approval was granted under the exempt
determination classification. Seventeen patients who had completed treatment for prostate
carcinoma with lymph node involvement were then retrospectively selected. Patients included in
study had a mean age of 72.9 years and were all under the care of the same radiation oncologist
at the same hospital between March 2019 and January 2021. Dose prescription was a
standardized regimen for all cases consisting of 4500 centiGray (cGy) in 25 fractions at 180 cGy
per fraction to the planning tumor volume (PTV) with nodal involvement (PTV45) followed by a

sequential boost of 3420 cGy in 19 fractions at 180 cGy per fraction to the primary tumor
volume. Diagnosed stage of disease for patients was T1c, N0, M0 with tumor grade (G) varying
between G1 to G5. One patient was excluded due the treatment of additional separate pelvic
nodes within the aforementioned prescribed dose regimen during the course of the prostate
treatment.
Patients were simulated with a GE Discovery RT (GE Medical Systems) CT scanner
using 2.5 mm slices in the head-first supine position. During simulation, customized lower
vaclocks were used for immobilization of the lower body with arms placed on chest and
headrests used for head position. Target volumes were all contoured by the same radiation
oncologist in charge of the patients’ care. Tumor volumes for PTV45 had a mean of 788.8 cm 3
with boost target volumes having a mean volume of 137.4 cm 3. Critical structures were
contoured by certified medical dosimetrists and approved by the treating oncologist. Organs
evaluated for the purpose of this study were the rectum, bladder, small bowel, and combined
femoral heads with mean volumes of 66.1 cm3, 186.6 cm3, 751.1 cm3, 354.5 cm3
respectively. Patient and tumor characteristics are shown on Table 1.
Planning Techniques
Treatment planning was completed with Eclipse treatment planning system (version 15.5)
using analytical anisotropic algorithm (AAA, version 15.5.12) for dose calculation with a grid
size of 2.5 mm. All patients were planned using flattening filter free (FFF) 10 MV photons for
treatment and a set maximum dose rate of 2400 MU/min on a Varian Truebeam (Varian Medical
Systems) linear accelerator with a Millennium 120 MLC system. Plan objectives included 100%
of prescription dose covering 95% of target tumor volume and a global max dose of less than or
equal to 110% of the prescription dose. Optimization criteria for both PTV45 and boost plans

was geared to meet plan coverage objectives while minimizing dose to surrounding normal
tissue. They included an upper objective to tumor volumes of 105% of the prescribed dose to
reduce high doses and lower objective of 100% of the prescribed dose to meet coverage goals.
Optimization criteria for regional critical organs included upper objectives of up to 105% of
prescription dose and other upper objectives points meant to aid in meeting particular dose
limitation goals. Dose constraints for OARs were doctor specific and based on established
guidelines and Radiation Therapy Oncology Group (RTOG) protocols for prostate cancer.
JT VMAT plans for treatment of the PTV45 were created by placing the isocenter at the
center of the volume. To obtain adequate tumor volume coverage, a fixed collimator angle of 30°
was used for the clockwise (CW) arc and an angle of 330° used for the counterclockwise (CCW)
arc. Jaw width was widened in the X and Y directions to ensure the entire target volume was
encompassed throughout treatment arc delivery with two full arcs. Jaw tracking function was
also activated during plan optimization.
The SF-FJ VMAT plans for the PTV45 were created by duplicating the JT VMAT plans.
The planning optimization objectives and machine parameters remained identical. Differences in
the plan parameters included the jaw tracking function, collimator, and the arc settings. Using the
same isocenter as the JT VMAT plans, two full CW and one full CCW arcs were created in the
SF-FJ VMAT plans. In order to have optimal dose modulation from the MLCs, the collimator
angle for the CW full arcs were set to 90° with X and Y jaws adjusted and fixed to encompass
the primary tumor volume. Initial CCW full arcs were given collimator angles of between 0° and
30° based on target coverage needs and set to rotate from 179° to 0°. Similarly, secondary CCW
half-arcs used a collimator angle of between 330° and 0° and set to rotate between 0° and 180°.
Jaw widths were fixed to less than or equal to 15cm in the X direction and Y jaws were adjusted

to encompass tumor volume as appropriate. The PTV45 fields for Patient 3 are displayed in
Figure 1.
Only one boost plan was created for each patient. The same boost plan was used for both
plan composites for the JT VMAT and SF-FJ VMAT plans. This was done to ensure a valid
comparison focused on evaluating the effects the different techniques used to treat the primary
tumor and involved lymph nodes had on the overall treatment plan. The isocenter for the boost
plan was moved to the center of the primary tumor volume and plans were composed of 2 full
arcs, CW and CCW, with collimator angles of 30° and 330°. Fields were widened to focus and
encompass on prostate. Jaw tracking function was activated during plan optimization and the
plan was renormalized to have 100% of the dose cover 95% of the target volume. The plan sum
feature in Eclipse was then used to combine PTV45 and boost plans for both SF-FJ and JT
VMAT techniques into composite plans to generate accurate dosimetric data and dose value
histograms (DVH). Beam arrangements of each technique are shown in Figure 2.
Plan Evaluation
Tumor dose coverage and dose received by OARs was evaluated through a comparison
of DVH data. To assess tumor volume coverage and conformity, the homogeneity index (HI) and
conformity index (CI) were used. According to the International Commission on Radiation
Units and Measurements (ICRU) Report 8312, HI is defined using the following formula:
𝐻𝐼 =

(

%

𝐶𝐼 100% =

%)
%

. For dose conformity to the target structures, the CI was calculated as:
%

included V105% (%), D2%, and mean dose.

. Additional parameters used to evaluate PTV dosage

Dose to critical structures was evaluated utilizing mean and max dose for all OARs as
well as the V30, V50, V60, V70 for the rectum and V30, V50, V70, V80 for the bladder. Small bowel
and combined femurs were assessed through the V 30, V40, V45 (cc) parameters and the V40
respectively. Monitor units needed for each plan sum was also evaluated to determine efficiency
of treatment plans. Statistical analysis of dosimetric results was thereafter performed using
paired t-tests with p < 0.05 considered statistically significant.

Results
This study aimed to draw a contrast between two different VMAT planning methods for
the treatment of prostate cancer with lymph node involvement and assess the potential
advantages of a SF-FJ VMAT technique over a JT VMAT plan. The use of identical boost plans
for each patient achieved the goal of having the variations found in the composite plans be
attributed to differences in PTV45 plans of the prescribed dose regimen. A notable difference
was seen between the average MUs of the SF-FJ VMAT (M = 1028.04, SD = 149.45) and JT
VMAT (M = 746.47, SD = 139.29) plans as shown on Table 2, t(15) = 5.63, p < .0001. At
281.57 MUs, the difference in average MUs between planning methods was substantial.
PTV45 coverage
Coverage evaluation for each technique was carried out by comparing the calculated CI
and HI for the PTV45. Average CI (M = 0.99, SD = 0.01) and HI (M = 0.77, SD = 0.02) was
equal among plans in both techniques, t(15) = -1.32, p = 0.2054, t(15) = 0.23, p = 0.8228.
Average plan max dose and mean dose received by the PTV45 were found to not have a
statistically significant difference. Overall PTV45 mean dose and average plan max dose were
very similar in SF-FJ VMAT (M = 5536.54, SD = 184.08), (M = 8474.98, SD = 44.25) and JT

VMAT (M = 5536.71, SD = 188.21), (M = 8487.63, SD = 73.25) plans, t(15) = -0.08, p = 0.9402,
t(15) = -0.98, p = 0.3449.
Other statistically significant differences identified during the evaluation of tumor
volume dose coverage were in the PTV45 V105% (%) and D2% parameters. Beginning with volume
covered by 105% of the prescription dose, it was found to be lower when using the split-field (M
= 1.0, SD = 1.16) technique compared to the jaw tracking (M = 1.34, SD = 1.52) plans, t(15) = 2.25, p = 0.0402. In a similar manner, the average PTV45 D2% in SF-FJ VMAT (M = 8263.84,
SD = 52.82) plans was lower compared to the JT VMAT (M = 8278.23, SD = 54.54) plans, t(15)
= -4.33, p = 0.0006.
Bladder
For the bladder, a dose-volume evaluation was carried out that included assessing low
and high dose regions of the organs. Areas evaluated for the bladder where there was no
statistically significant difference found between techniques were in the V 30, V50, and max dose
received. Differences in the radiation dose received can be seen in the V 50, V80, and mean dose to
the bladder. Evaluation results showed a statistically significant difference in the V 50 of the
bladder with the split-field (M = 30.67, SD = 18.38) plans having an average lower value than
that of the jaw tracking (M = 33.01, SD = 18.55) plans, t(15) = -5.78, p < 0.0001. The bladder
V80 was also on average less in the JT VMAT (M = 5.22, SD = 4.21) plans than in the SF-FJ
VMAT (M = 5.87, SD = 4.50) plans, t(15) = 2.43, p = 0.0282. In contrast, mean dose received
by the bladder was greater when treating using the jaw tracking (M = 4507.34, SD = 826.21)
technique compared to the split-field (M = 4465.12, SD = 818.90) plans as shown on Table 3,
t(15) = -5.78, p < 0.0001.

Small bowel
Small bowel comparison included measuring the area receiving 45 Gy in cubic
centimeters (cc) which, among others, is a common constraint used when treating pelvic cancers.
Both techniques showed similar results in terms of this metric in addition to the mean dose, V 30,
and V40 with no statistically significant differences found. Minimal variance was also noted
regarding average max dose received by this radiosensitive organ in the JT VMAT (M =
4736.64, SD = 216.37) and SF-FJ VMAT (M = 4738.93, SD = 219.36) plans, t(15) = 0.14, p =
0.8915.
Rectum
Another important organ to consider in the treatment of prostate cancer with involved
pelvic lymph nodes, the rectum was additionally evaluated using dose-volume distribution data.
Results for the percentage of area covered by the V 30, V50, V60, and V70 were found to be
comparable between treatment techniques with no statistically significant differences. Likewise,
no meaningful variance was noted in the average max and mean doses between SF-FJ VMAT
and JT VMAT plans.
Femurs
Along with max and mean dose comparisons, combined femurs were furthermore
assessed in terms of the percentage of area covered by 40 Gy. Both techniques showed little
differences in this metric along with mean dose to the combined femurs. In contrast, max dose to
these critical structures in the SF-FJ VMAT (M = 4557.63, SD = 395.81) plans did have

differences that were statistically significant with JT VMAT (M = 4659.27, SD = 374.02) plans,
t(15) = -2.58, p = 0.0207.

Discussion
This study was conducted with the goal of determining the effectiveness of a static jaw
planning technique over that of a jaw tracking technique for the treatment of prostate cancer with
involved lymph nodes. Mechanical limitations found in Varian linacs lead to restrictions in the
travel length of MLCs utilized to modulate dose delivered over the course of a patient’s
treatment. In the case of large target structures, this can impact the quality of tumor coverage as
well as conformity and homogeneity of the dose delivered. Possible advantages of one treatment
planning method over another could result in minimizing side effects and improved patient
outcomes.
A consideration that should be kept in mind when treatment planning is the length of time
a patient will be laying on the table in treatment position. For this reason, and to increase
comparability, an attempt was made by the researcher to maintain an equal number of arcs for
the treatment of the PTV45 in all plans. This was found to be unachievable during the
optimization process for the SF-FJ VMAT plans resulting in the initial plans of each dose
regimen having three full arcs compared to only needing two arcs in the JT VMAT plans. As a
consequence of adding a third arc there was a considerable difference in MUs between
techniques. The amount of MUs calculated in a plan are an indication of not only the duration of
the treatment, but also of possible development of secondary cancers in the future. In a study by
Verellen et al.13 higher MUs were observed to be associated with higher integral dose and a
higher probability of radiation-induced cancers. In this aspect, the fixed-jaw plans fall short.

PTV45 coverage
For PTV45 coverage, the CI and the HI average values computed from the final composite
plans for each patient were equal after a comparison was done among techniques. Originally
proposed by the RTOG in 1993 to evaluate dose conformity, the CI was defined for the purpose
of this paper as the ratio of the volume covered by 100% isodose line to the total volume of the
PTV4514. Along the same lines, uniform dose delivery has been historically measured using the
HI with zero thought of as the ideal value15. With both techniques yielding the same values in
each of these metrics, the hypothesized advantage by the SF-FJ VMAT technique was not
observed. It is noteworthy, however, that while similar studies have found the same results in
regard to the CI, an advantage is sometimes shown by one technique when it comes to the HI 7,15.
In assessing the overall quality of a treatment plan and target coverage, global max dose
and tumor volume mean dose should be considered. Quality radiotherapy plans aim to control
the max dose as much as possible, without sacrificing coverage, in order to control radiationinduced side effects in the patient. Mean doses of target structures provide a general measure of
how well they are covered by a given radiation dose and allows for a comparison of coverage
between plans. Results of the study showed the average global max dose for SF-FJ VMAT
techniques to be slightly better with no statistically significant advantage found. Additionally,
average mean dose for the PTV45 was found to be almost identical among techniques. This
result was unexpected as the researcher believed the use of smaller-sized fields during the
planning stage would yield better dose modulation and results in these metrics than the JT
VMAT plans. Results obtained could be due to the use of identical maximum and minimum
optimization objectives for the target volume along with similar machine parameters during
treatment planning.

An area that did provide a measure of contrast between techniques was in the evaluation
of high-dose volumes for certain structures. Specifically, the V 105% (%) and D2% for the PTV45
were found to be, in a statistically significant way, lower on average in the SF-FJ VMAT plans.
Controlling the amount of volume receiving high doses of radiation serves to reduce the
incidence of late and acute toxicities in normal tissues including skin fibrosis and radiation
dermatitis2. In general, both techniques demonstrated the ability to minimize high-dose regions
fairly well. Still, the use of split-fields with fixed-jaws was expected to yield improved radiation
dose delivery resulting in superior control of high dose volumes.
Bladder
The bladder was yet another structure that showed a dosimetric difference between
planning methods. Interestingly, while mean dose and V 50% were on average lower in the SF-FJ
VMAT plans, V80% was shown to have a statistically significant larger value than in the JT
VMAT plans. Even so, mean dose to the bladder was still on average lower in the fixed-jaw
plans. The fact that a greater area was covered by 80 Gy when SF-FJ VMAT techniques were
used could be attributed to the use of a 3rd arc focused solely on the prostate which also included
involved bladder in the field. This, in conjunction with the boost plan fields and parts of the
lymph node-focused arcs in the PTV45 plans that treated the same area with portions of involved
bladder, could have contributed to the statistically significant larger high-dose volume.
Small bowel
Regarding the small bowel, there was no statistically significant dosimetric advantage
shown by either technique when comparing any of the dose-volume relationships such as
V45(cc), V30, and V40. Of particular importance, the V45 was a metric that QUANTEC

recommended should be minimized in the bladder to less than 195cc during pelvic radiation
therapy to control late toxicity16. Both techniques effectively reduced the high-dose volume in
this radiosensitive organ resulting in constraints and sparing goals being met in accordance with
doctor directives.
Rectum
Similarly, a dosimetric evaluation of the rectum showed no clear advantage in one
particular method over another. Although an advantage was expected to be exhibited by the SFFJ VMAT technique, comparable results have been described in previous clinical literature. For
example, when comparing field size restricted VMAT plans in vulvar and anorectal cancer
patients, Rossi et al.8 found no statistically significant differences in dose received by the rectum.
Regardless, our study showed dose-volume goals to still be well under what was requested by the
treating physician in all plans.
Femurs
An instance of an important difference between techniques was seen when analyzing the max
doses in the combined femurs. JT VMAT plans were found to have a statistically significant
higher average max dose in these critical structures. In order to reduce femoral head and neck
fractures, it is critical for patients undergoing pelvic radiotherapy to have the radiation dose
received by the femoral bones be less than 45 to 50 Gy 18. While the average max doses were
within tolerance for both techniques, SF-FJ VMAT plans had a max dose that was 1.02 Gy less
on average. In this case, using the fixed-jaw technique had a clear dosimetric advantage resulting
in greater dose sparing.

Limitations and future research
This research did not consider MLC or jaw transmission which can be considered a limitation
of the study and has the potential to be considerably different between techniques. Along with
radiation transmission, future research could evaluate different modalities, such as tomotherapy,
against jaw-tracking and static-field techniques for treatment of advanced prostate cancer. Other
comparisons may include split-field techniques with different setups such as the use of fixed-jaw
arcs focused on the inferior and superior portions of the PTV45.

Conclusion
Radiotherapy treatments of target structures with sizeable volumes, such as in the case of
prostate cancer with positive pelvic nodes, can be involved and complicated. Sub-optimal dose
modulation resulting from mechanical limitations in linacs can affect tumor coverage as well as
conformal and homogenous dose delivery. To assess the performance of certain techniques when
considering this possible mechanical drawback, this study evaluated variables such as PTV45
coverage, dose conformity, and dose homogeneity as well as dose-volume distribution of the
bladder, rectums, femurs, and small bowel. Analysis of DVH data determined statistically
significant dosimetric differences in the bladder, femurs, and high-dose regions of the tumor
volume. Although results overall showed most advantages to be in favor of the SF-FJ VMAT
plans, the longer treatment times as a result of the higher MUs and additional arc for treatment of
PTV45 leaves the cost-benefit of this technique to still be decided. Ultimately, the decision will
be physician dependent as to whether the dosimetric benefits are enough to overcome the
drawback of the longer time the patient will be on the treatment table.
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Table 1
Patient, tumor, and OAR characteristics.
Patient Stage

Grade PTV45
Volume
(cm3)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

G5
G3
G5
G3
G2
G2
G2
G2
G4
G2
G1
G4
G5
G5
G5
G5

T1c, N0, M0
T1c, N0, M0
T1c, N0, M0
T1c, N0, M0
T1c, N0, M0
T1c, N0, M0
T1c, N0, M0
T1c, N0, M0
T1c, N0, M0
T1c, N0, M0
T1c, N0, M0
T1c, N0, M0
T1c, N0, M0
T1c, N0, M0
T1c, N0, M0
T1c, N0, M0

854.7
844.3
707.8
849.3
789.2
673.5
819.4
590.2
803.2
815.4
653.3
964.2
624.1
996.8
831
804.3

Boost
Tumor
Volume
(cm3)
92.6
182.4
100
139.5
162.5
109.3
127
120.3
114
134.8
132.1
237.4
118.1
154
138.3
136.7

Bladder Rectum
Volume Volume
(cm3)
(cm3)

Femurs Small
Volume Bowel
(cm3)
(cm3)

291.3
338.7
228.2
247.5
230.8
125.2
80.6
73.7
267.6
153.9
277.6
92.4
121.2
94
39.3
323.6

324.3
468.7
331.3
305.7
346.9
356.3
322.9
406.1
363.7
397.1
317.8
419.3
100.3
374.2
370.6
278.8

77.8
77
63.6
100
76.5
83.6
41.2
63.2
28.1
112.6
74.9
46.6
37.4
37.5
77
61.1

1364.4
258
479.7
617.5
1340.4
497
1152.7
263.6
462.9
1254.2
695.3
404.5
325.8
955.9
985.4
960.5

Table 2
Comparison of dosimetric tumor parameters between SF-FJ VMAT and JT VMAT treatment
techniques (x̅ ± SD)
Parameters
Composite Plan
Dmax (cGy)
PTV45
CI100%
HI
V105% (%)
D2% (cGy)
Dmean (cGy)
Monitor Units (MUs)

SF-FJ VMAT

JT VMAT

p-value

8474.98 ± 44.25

8487.63 ± 73.25

0.3449

0.99 ± 0.01
0.77 ± 0.02
1.0 ± 1.16
8263.84 ± 52.82
5536.54 ± 184.08
1028.04 ± 149.45

0.99 ± 0.01
0.77 ± 0.02
1.34 ± 1.52
8278.23 ± 54.54
5536.71 ± 188.21
746.47 ± 139.29

0.2054
0.8228
0.0402
0.0006
0.9402
0.0001

Table 3
Comparison of OAR doses between SF-FJ VMAT and JT VMAT treatment techniques (x̅ ± SD)
Parameters
Bladder
V30 (%)
V50 (%)
V70 (%)
V80 (%)
Dmax (cGy)
Dmean (cGy)
Rectum
V30 (%)
V50 (%)
V60 (%)
V70 (%)
Dmax (cGy)
Dmean (cGy)
Femurs
V40 (%)
Dmax (cGy)
Dmean (cGy)
Small Bowel
V30 (%)
V40 (%)
V45 (cc)
Dmax (cGy)
Dmean (cGy)

SF-FJ VMAT

JT VMAT

p-value

78.63 ± 18.45
30.67 ± 18.38
13.34 ± 9.19
5.87 ± 4.5
8319.06 ± 102.82
4465.12 ± 818.9

78.05 ± 18.4
33.01 ± 18.55
13.58 ± 8.84
5.22 ± 4.21
8317.61 ± 107.96
4507.34 ± 826.21

0.5962
0.0001
0.1864
0.0282
0.9044
0.0465

65.68 ± 15.6
23.37 ± 6.32
17.46 ± 4.87
12.25 ± 3.71
8282.28 ± 91.42
3966.8 ± 434.44

62.97 ± 13.89
23.99 ± 5.65
17.77 ± 4.447
12.15 ± 3.49
8302.52 ± 95.73
3932.01 ± 398.5

0.0633
0.0542
0.0988
0.5136
0.0634
0.1597

1.07 ± 1.25
4557.63 ± 395.81
1951.81 ± 341.96

1.44 ± 1.22
4659.27 ±374.02
1976.78 ± 327.18

0.1313
0.0207
0.2702

12.26 ± 8.08
3.33 ± 2.35
7.26 ± 8.28
4738.93 ± 219.36
1573.15 ± 455.93

12.26 ± 8.08
3.35 ± 2.59
7.03 ± 8.79
4736.64 ± 216.37
1592.55 ± 460.17

0.7311
0.9254
0.8189
0.8915
0.3741

Figure 1. SF-FJ VMAT PTV45 fields for Patient 3.

Figure 2. Beam arrangements for Patient 3 of composite plans for each technique.

